Vicore Pharma to present Phase 2b ASPIRE-IPF trial design data at ERS Congress 2026

• Vicore Pharma will attend the European Respiratory Society Congress 2026 in Barcelona and online on Sept. 5-9, 2026.
• Buloxibutid Phase 2b ASPIRE-IPF trial design and baseline patient characteristics scheduled for oral presentation on Sept. 7, 2026 at 11:35 CEST.
• Translational data on AT2 receptor activation in alveolar epithelial type II cells, linked to MMP-13, set for poster on Sept. 6, 2026 at 12:30 CEST.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vicore Pharma Holding AB published the original content used to generate this news brief on August 24, 2026, and is solely responsible for the information contained therein.